Online inquiry

IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14863MR)

This product GTTS-WQ14863MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14863MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8483MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ14704MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ3514MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ3339MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ1543MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ13244MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ8787MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ9929MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KB-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW